B
JANX icon

Bailard’s Janux Therapeutics JANX Stock Holding History

Bailard’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,500
Closed -$348K – 789
2024
Q4 		$348K Sell
6,500
-900
-12% -$47.6K 0.01% 528
2024
Q3 		$336K Hold
7,400
– – 0.01% 537
2024
Q2 		$310K Hold
7,400
– – 0.01% 537
2024
Q1 		$279K Buy
+7,400
New +$161K 0.01% 577

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Bailard's JANX Position: Q1 2025 in Review

Bailard sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 6,500 shares — an estimated $348K sold.

Bailard first reported a position in JANX in Q1 2024 and held it in 4 quarters. The position peaked at $348K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Bailard reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bailard sold 6,500 Janux Therapeutics shares in Q1 2025, an estimated $348K.
  • Bailard first reported a position in Janux Therapeutics in Q1 2024 and held it in 4 quarters.
  • Bailard's Janux Therapeutics position peaked at $348K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Bailard's 13F filing for Q1 2025, filed 2 May 2025.